1
Robert A Galemmo Jr, Celia Dominguez, John M Fevig, Qi Han, Patrick Y Lam, Donald J P Pinto, James R Pruitt, Mimi L Quan: Inhibitors of factor Xa with a neutral P1 specificity group. DuPont Pharmaceuticals Company, David H Vance, December 7, 1999: US05998424 (76 worldwide citation)

The present application describes inhibitors of factor Xa with a neutral P1 specificity group of formula I: ##STR1## or pharmaceutically acceptable salt forms thereof, wherein R and E may be groups such as methoxy and halo.


2

3

4

5
Wayne Bowen, Brian R de Costa, Celia Dominguez, Xiao Shu He, Kenner C Rice: Aralkyl bridged diazabicycloalkane derivatives for CNS disorders. The United States of America represented by the Department of Health and Human Services, Leydig Voit & Mayer, October 21, 1997: US05679673 (31 worldwide citation)

Certain aralkyl diazabicycloalkyl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychoses and convulsions. Compounds of particular interest are of the formula: ##STR1## wherein each of R, R.sup.1, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is independently selected fro ...


6

7
Celia Dominguez, Joseph Cacciola, John Matthew Fevig: Imidazole containing aminoboronic acids. The DuPont Merck Pharmaceutical Company, June 17, 1997: US05639739 (21 worldwide citation)

The present invention relates generally to .alpha.-aminoboronic acids and corresponding peptide analogs of the formula (I): ##STR1## in which the .alpha.-carbon is substituted with an optionally functionalized imidazole containing alkyl group. These compounds are useful as inhibitors of trypsin-like ...


8
Celia Dominguez, Qi Han, Daniel Emmett Duffy, Jeongsook Maria Park, Mimi Lifen Quan, Karen Anita Rossi, Ruth Richmond Wexler: Amidinoindoles, amidinoazoles, and analogs thereof. E I du Pont de Nemours and Company, David H Vance, March 28, 2000: US06043257 (20 worldwide citation)

The present application describes amidinoindoles, amidinoazoles, and analogs thereof of formula I: ##STR1## wherein W, W.sup.1, W.sup.2, and W.sup.3 are selected from CH and N, provided that one of W.sup.1 and W.sup.2 is C(C(.dbd.NH)NH.sub.2) and at most two of W, W.sup.1, W.sup.2, and W.sup.3 are N ...


9
Guoqing Chen, Jeffrey Adams, Jean Bemis, Shon Booker, Guolin Cai, Lucian Di Pietro, Celia Dominguez, Daniel Elbaum, Julie Germain, Stephanie Geuns Meyer, Michael Handley, Qi Huang, Joseph L Kim, Tae Seong Kim, Alexander Kiselyov, Xiaohu Ouyang, Vinod F Patel, Leon M Smith, Markian Stec, Andrew Tasker, Ning Xi, Shimin Xu, Chester Chenguang Yuan, Michael Croghan: Substituted alkylamine derivatives and methods of use. Amgen, Joseph W Bulock, February 7, 2006: US06995162 (13 worldwide citation)

Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis a ...


10
Tae Seong Kim, Steven Bellon, Shon Booker, Noel D Angelo, Celia Dominguez, Ingrid Fellows, Matthew Lee, Longbin Liu, Elizabeth Rainbeau, Aaron C Siegmund, Andrew Tasker, Ning Xi, Yuan Cheng: Substituted heterocycles and methods of use. Amgem, January 26, 2010: US07652009 (12 worldwide citation)

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and ...